A Comprehensive Review of Emerging Biomarkers ACNG4, CHRNA6, PKMYT1 And EPYC And Their Role In Breast Cancer Diagnosis And Treatment
DOI:
https://doi.org/10.63682/jns.v14i3.4101Keywords:
Breast cancer, Biomarkers, ACNG4, CHRNA6,, PKMYT1, EPYCAbstract
Breast cancer remains one of the most significant threats to women’ health that calls for identification, development and improvement of diagnostic markers, prognostic indicators and therapeutic targets. Several molecular markers including HER2, ER and BRCA1/2 have contributed to the treatment of breast cancer but they are inadequate especially in the aggressive and therapy-resistant tumors like the triple negative breast cancer. The new biomarkers—ACNG4, CHRNA6, PKMYT1, and EPYC—provide better modalities than previous approaches by providing better understanding of tumor behaviour, diagnosis, and treatment. ACNG4 and CHRNA6 are potential biomarkers targets for early diagnosis and for enrolment of breast cancer aggressive subtypes while PKMYT1 is a promising biomarker owing to its implication in cell cycle regulation and EPYC for its implication in tumour microenvironment. However, some limitations such as patient variability and the absence of standardized detection mechanism become hurdles to the application of these approaches in clinical settings. To elaborate each biomarker’s possibility and drawback, this review also evaluates the combination of those biomarkers with innovative technologies such as liquid biopsy and artificial intelligence to boost breast cancer treatment. Further studies and development of more elaborate approaches are needed in order to turn the biomarkers identified in this study into clinically stable and accurate measures that will help in the development of precision oncology and consequent individualized treatment protocols.
Downloads
Metrics
References
Golestan A, Tahmasebi A, Maghsoodi N, Faraji SN, Irajie C, Ramezani A. Unveiling promising breast cancer biomarkers: an integrative approach combining bioinformatics analysis and experimental verification. Bmc Cancer. 2024 Jan 31;24(1):155.
Ali NH, Maher FT. Comprehensive Biochemical Profiling of Key Serum Biomarkers in Breast Cancer Patients: Pre-and Post-Mastectomy Comparative Analysis. Journal of Computational Analysis and Applications (JoCAAA). 2024 May 28;33(06):890-8.
Albogami S. Comprehensive analysis of gene expression profiles to identify differential prognostic factors of primary and metastatic breast cancer. Saudi Journal of Biological Sciences. 2022 Jul 1;29(7):103318.
Mirza Z, Ansari MS, Iqbal MS, Ahmad N, Alganmi N, Banjar H, Al-Qahtani MH, Karim S. Identification of novel diagnostic and prognostic gene signature biomarkers for breast cancer using artificial intelligence and machine learning assisted transcriptomics analysis. Cancers.
2023 Jun 18;15(12):3237.
Deng JL, Xu YH, Wang G. Identification of potential crucial genes and key pathways in breast cancer using bioinformatic analysis. Frontiers in genetics. 2019 Aug 2;10:695.
James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP. BRCA1, a potential predictive biomarker in the treatment of breast cancer. The oncologist. 2007 Feb 1;12(2):142-50.
Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocrine-related cancer. 2010 Dec 1;17(4):R245-62.
Patani N, Martin LA, Dowsett M. Biomarkers for the clinical management of breast cancer: international perspective. International journal of cancer. 2013 Jul;133(1):1-3.
Sana M, Malik HJ. Current and emerging breast cancer biomarkers. Journal of cancer research and therapeutics. 2015 Jul 1;11(3):508-13.
Gu J, Huang W, Zhang J, Wang X, Tao T, Yang L, Zheng Y, Liu S, Yang J, Zhu L, Wang H. TMPRSS4 promotes cell proliferation and inhibits apoptosis in pancreatic ductal adenocarcinoma by activating ERK1/2 signaling pathway. Frontiers in oncology. 2021 Mar 18;11:628353.
Hadi NI, Jamal Q, Iqbal A, Shaikh F, Somroo S, Musharraf SG. Serum metabolomic profiles for breast cancer diagnosis, grading and staging by gas chromatography-mass spectrometry. Scientific reports. 2017 May 11;7(1):1715.
Hussain AM, Ali AH, Mohammed HL. Correlation between serum and tissue markers in breast cancer Iraqi patients. Baghdad Science Journal. 2022 Jun 1;19(3):0501-.
Shreya S, Shekher A, Puneet P, Prasad SB, Jain BP. Haematological and biochemical analysis of blood samples from early and late stage breast cancer patients in India. Bioinformation. 2023;19(7):806.
Laya A, Wangso H, Camargo JM, Siewe FB, Rashmi HB, Mathew NS, Destro PH, Junior GM, Koubala B, Bueno V. Trace elements homeostasis in biological samples as new candidate biomarkers for early diagnosis and prognostic of female breast cancer and therapeutic response: Systematic review: Biomarkers for early diagnosis of breast cancer. Archives of Breast Cancer. 2023;10(1):26-37.
Yao F, Yan C, Zhang Y, Shen L, Zhou D, Ni J. Identification of blood protein biomarkers for breast cancer staging by integrative transcriptome and proteome analyses. Journal of proteomics. 2021 Jan 6;230:103991.
Beksac K, Reçber T, Çetin B, Alp O, Kaynaroğlu V, Kır S, Nemutlu E. GC-MS Based Metabolomics Analysis to Evaluate Short-Term Effect of Tumor Removal on Patients with Early-Stage Breast Cancer. Journal of Chromatographic Science. 2023 Aug;61(7):612-8.
Afzal M, Noreen R, Aslam N, Alam MM, Momenah MA. Novel Noninvasive Serum Biomarkers for Prompt Diagnosis of Breast Carcinoma. ACS omega. 2023 Dec 21;9(1):1174-82.
Gajbhiye A, Dabhi R, Taunk K, Jagadeeshaprasad MG, RoyChoudhury S, Mane A, Bayatigeri S, Chaudhury K, Santra MK, Rapole S. Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes. Journal of proteomics. 2017 Jun 23;163:1-3.
Oloomi M, Moazzezy N, Bouzari S. Comparing blood versus tissue-based biomarkers expression in breast cancer patients. Heliyon. 2020 Apr 1;6(4).
Zia T, Bangfan L, Nadeem A, Hussain A, Abdel-Maksoud MA, Zakri AM, Bashir MK, Ali M, Jabeen N, Jamil M, Al-Qahtani WH. Comprehensive multi-level expression profiling of key biomarkers in breast cancer patients. American Journal of Translational Research. 2023;15(10):6058.
Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World journal of clinical oncology. 2014 Aug 8;5(3):412.
Pourteimoor V, Mohammadi-Yeganeh S, Paryan M. Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications. Tumor Biology. 2016 Nov;37:14479-99.
Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer—clinical applications. Nature reviews Clinical oncology. 2010 Dec;7(12):693-701.
Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. Journal of clinical oncology. 2005 Oct 10;23(29):7350-60.
Bertucci F, Birnbaum D, Goncalves A. Proteomics of breast cancer: principles and potential clinical applications. Molecular & Cellular Proteomics. 2006 Oct 1;5(10):1772-86.
Dieci MV, Miglietta F, Guarneri V. Immune infiltrates in breast cancer: recent updates and clinical implications. Cells. 2021 Jan 23;10(2):223.
Gasparini G, Bonoldi E, Gatti C, Vinante O, Toi M, Tominaga T, Gion M, Dittadi R,
Verderio P, Boracchi P, Hanatani M. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. Journal of the National Cancer Institute. 1997 Jan 15;89(2):139-47.
Smerage JB, Hayes DF. The prognostic implications of circulating tumor cells in patients with breast cancer. Cancer investigation. 2008 Jan 1;26(2):109-14.
Oparina N, Erlandsson MC, Fäldt Beding A, Parris T, Helou K, Karlsson P, Einbeigi Z, Bokarewa MI. Prognostic significance of BIRC5/Survivin in breast cancer: results from three independent cohorts. Cancers. 2021 May 4;13(9):2209.
Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. European urology. 2007 Dec 1;52(6):1601-9.
Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Senti C, Brambilla P, Milani M, Spada D. Breast cancer circulating biomarkers: advantages, drawbacks, and new insights. Tumor Biology. 2015 Sep;36:6653-65.
Purkayastha K, Dhar R, Pethusamy K, Srivastava T, Shankar A, Rath GK, Karmakar S. The issues and challenges with cancer biomarkers. Journal of Cancer Research and Therapeutics. 2023 Jan 1;19(Suppl 1):S20-35.
Gupta S, Venkatesh A, Ray S, Srivastava S. Challenges and prospects for biomarker research: a current perspective from the developing world. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics. 2014 May 1;1844(5):899-908.
Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L. Breast cancer: Biology, biomarkers, and treatments. International immunopharmacology. 2020 Jul 1;84:106535.
Solier C, Langen H. Antibody‐based proteomics and biomarker research—current status and limitations. Proteomics. 2014 Mar;14(6):774-83.
Safari F, Kehelpannala C, Safarchi A, Batarseh AM, Vafaee F. Biomarker Reproducibility Challenge: A Review of Non-Nucleotide Biomarker Discovery Protocols from Body Fluids in Breast Cancer Diagnosis. Cancers. 2023 May 16;15(10):2780.
Loke SY, Lee AS. The future of blood-based biomarkers for the early detection of breast cancer. European journal of cancer. 2018 Mar 1;92:54-68.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
